Inflazyme announces asthma Phase I results

Inflazyme (TSE:IZP) said results from its U.K. Phase I trial with IPL576,092, an oral treatment for asthma, show the compound was safe and well tolerated. IZP plans to initiate Phase IIa studies mid-y...